Tepoxalin
Based on 1 Customer Validation
Tepoxalin is an orally active dual inhibitor of Cyclooxygenase/Lipoxygenase, with IC50 values of 4.6 μM (sheep cyclooxygenase), 2.85 μM (rat cyclooxygenase), 0.15 μM (rat 5-lipoxygenase), and 3.0 μM (h12-lipoxygenase), respectively. Tepoxalin inhibits ROS production and NF-κB activation. Tepoxalin suppresses the production of thromboxane B2, leukotriene B4, prostaglandins and cytokines, and blocks platelet aggregation. Tepoxalin exhibits potent anti-inflammatory activity in rats with adjuvant-induced arthritis. Tepoxalin possesses analgesic activity. Tepoxalin shows no ulcerogenic activity within the anti-inflammatory dose range. Tepoxalin can be used in studies related to adjuvant-induced arthritis, skin inflammation and Alzheimer's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.46%
- CAS No.: 103475-41-8
- Formule: C20H20ClN3O3
- Masse moléculaire:385.84
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Pyroptosis Compound Library
HY-L059
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Anti-Liver Cancer Compound Library
HY-L101
-
Antidepressant Compound Library
HY-L108
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Cancer Stem Cells Compound Library
HY-L135
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Anti-Hematopathy Compound Library
HY-L171
-
Immunopotentiator Compound Library
HY-L172
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Activité biologique
|
Sheep cyclooxygenase 4.6 μM (IC50) |
Rat cyclooxygenase 2.85 μM (IC50) |
Rat 5-lipoxygenase 0.15 μM (IC50) |
h12-lipoxygenase 3.0 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RBL-1 | IC50 |
0.15 μM
Compound: Tepoxalin
|
Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
|
[PMID: 10230624] |
| RBL-1 | IC50 |
0.15 μM
Compound: Tepoxalin
|
The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1
The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1
|
[PMID: 1635053] |
| RBL-1 | IC50 |
1.7 μM
Compound: Tepoxalin
|
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
|
[PMID: 10230624] |
| RBL-1 | IC50 |
2.85 μM
Compound: Tepoxalin
|
Inhibitory activity against cyclooxygenase (COX) in intact rat barophilic leukemia cells (RBL-1)
Inhibitory activity against cyclooxygenase (COX) in intact rat barophilic leukemia cells (RBL-1)
|
[PMID: 10230624] |
| RBL-1 | IC50 |
4.2 μM
Compound: Tepoxalin
|
Inhibitory activity against Cyclooxygenase (COX) using broken rat barophilic leukemia cells (RBL-1)
Inhibitory activity against Cyclooxygenase (COX) using broken rat barophilic leukemia cells (RBL-1)
|
[PMID: 10230624] |
Tepoxalin inhibits ovine seminal vesicle cyclooxygenase with an IC50 of 4.6 μM[1].
Tepoxalin inhibits cyclooxygenase in RBL-1 lysates with an IC50 of 2.85 μM[1].
Tepoxalin inhibits cyclooxygenase activity in intact RBL-1 cells with an IC50 of 4.2 μM[1].
Tepoxalin inhibits the production of thromboxane B2 in peripheral blood leukocytes stimulated by calcium ionophore A-23187, with an IC50 of 0.01 μM[1].
Tepoxalin inhibits the production of thromboxane B2 in whole blood stimulated by calcium ionophore A-23187, with an IC50 of 0.08 μM[1].
Tepoxalin inhibits epinephrine-induced platelet aggregation with an IC50 of 0.045 μM[1].
Tepoxalin inhibits lipoxygenase in RBL-1 lysates with an IC50 of 0.15 μM[1].
Tepoxalin inhibits lipoxygenase activity in intact RBL-1 cells with an IC50 of 1.7 μM[1].
Tepoxalin inhibits the production of leukotriene B4 in peripheral blood leukocytes stimulated by calcium ionophore A-23187, with an IC50 of 0.07 μM[1].
Tepoxalin inhibits leukotriene B4 production in whole blood stimulated by the calcium ionophore A-23187, with an IC50 of 1.57 μM[1].
Tepoxalin inhibits platelet 12-lipoxygenase with an IC50 of 3.0 μM[1].
Tepoxalin weakly inhibits 15-lipoxygenase with an IC50 of 157 μM[1].
Tepoxalin inhibits PMA-induced Mac-1 upregulation and PMA-induced IL-8 production in HL60 granulocytes[2].
Tepoxalin (1-30 μM; 16 h-96 h) potently inhibits the proliferation of activated peripheral blood lymphocytes (PBL) and IL-2-dependent T lymphoblasts, with the strongest inhibitory activity against PBL stimulated by PMA, PMA + ionomycin, and IL-2 (IC50 values 1.36-2.75 μM), while exerting minimal effects on spontaneously proliferating or growth factor-dependent cell lines; in addition, it synergizes with suboptimal doses of cyclosporin A (CsA) to inhibit OKT3-stimulated PBL proliferation[3].
Tepoxalin (1-50 μM; 30 min pre-incubation; 24 h LPS stimulation) potently inhibits LPS-induced IL-1β and IL-6 synthesis in primary rat microglia, with the maximum inhibitory effect observed at 10 μM[4].
Tepoxalin (1-50 μM; 30 min pre-incubation; 24 h IL-1β stimulation) potently inhibits IL-1β-induced IL-6 synthesis in primary rat astrocytes, with the maximum inhibitory effect observed at 10 μM[4].
Tepoxalin (1-50 μM; pre-incubation; 60 min IL-1β stimulation) dose-dependently inhibits IL-1β-induced IκB-α degradation in human U373 MG astrocytoma cells[4].
Tepoxalin inhibits cyclooxygenase activity in purified ovine PGHS1 in a non-competitive and reversible manner, with an IC50 of 0.1 μM, and this inhibitory effect cannot be reversed by excess heme[5].
Tepoxalin inhibits the peroxidase activity of purified ovine PGHS1 with an IC50 of 4 μM. This effect is independent of cyclooxygenase activity, can be reversed by excess heme, and does not inhibit unrelated peroxidases[5].
Tepoxalin (20 μM; 1 h at 37°C) inhibits tert-butyl hydroperoxide-induced reactive oxygen species production and prostaglandin E2 synthesis in Jurkat cells at a concentration of 20 μM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human peripheral blood lymphocytes (PBLs), IL-2-dependent T cell blasts, Jurkat cells, PDGF-supplemented 3T3 cells, T47D cells, MCF7 cells
-
Concentration:1-30 μM (stimulated PBLs, IL-2-dependent blasts); up to 20 μM (Jurkat, PDGF-supplemented 3T3, T47D, MCF7 cells); 10, 30 μM (timed addition assays); 2 μM (combination assay with CsA)
-
Incubation Time:72-96 h (stimulated PBLs); 16 h (IL-2-dependent blasts); 3 days (Jurkat, PDGF-supplemented 3T3, T47D, MCF7 cells, combination assay); 48-72 h total (timed addition assays); 24 h (viability assays)
-
Result:Suppressed PBL proliferation stimulated by OKT3, PMA, PMA + ionomycin, or IL-2, with mean IC50 values of 5.9 μM, 1.36 μM, 1.6 μM, and 2.75 μM, respectively.
Caused near-complete suppression of IL-2-dependent blasts at 10 μM.
Exerted minimal effect on proliferation of Jurkat, PDGF-supplemented 3T3, T47D, or MCF7 cells at concentrations up to 20 μM.
Showed equivalent potency when added at culture initiation or 48 hours post-OKT3 stimulation.
Co-administration of 2 μM tepoxalin with 0.1 nM CsA resulted in 40% suppression of OKT3-stimulated PBL proliferation, and with 0.4 nM CsA resulted in 45% suppression.
Maintained 90-95% cell viability at 20 μM after 24 hours.
-
Cell Line:human PBLs, IL-2-dependent T cell blasts
-
Concentration:30 μM (OKT3-stimulated PBLs); 1-30 μM (PMA + ionomycin-stimulated PBLs); 15, 30 μM (PMA-stimulated PBLs); 10 μM (IL-2-dependent blasts)
-
Incubation Time:2 h pre-incubation, then 2, 4, or 21 h post-OKT3 stimulation; 2 h pre-incubation, then 4 h post-PMA + ionomycin stimulation; 2 h pre-incubation, then 4 h post-PMA stimulation; 2 h (IL-2-dependent blasts)
-
Result:Caused only minimal (≤1.8-fold) reduction in OKT3-induced IL-2 mRNA at 2, 4, and 21 hours post-stimulation.
Induced dose-dependent reduction of IL-2 mRNA in PMA + ionomycin-stimulated PBLs, with 2.7-fold reduction at 1 μM, 4.2-fold at 5 μM, 8.3-fold at 10 μM, and 12.5-fold at 30 μM.
Caused 6.1-fold reduction of IL-2 mRNA at 15 μM and 27-fold reduction at 30 μM in PMA-stimulated PBLs, with no effect on G3PDH mRNA levels.
Caused more than 4.5-fold reduction of IFN-γ mRNA in IL-2-dependent blasts at 10 μM.
-
Cell Line:human U373 MG astrocytoma cells
-
Concentration:1, 10, 25, 50 μM
-
Incubation Time:pre-incubation; 60 min IL-1β stimulation
-
Result:Dose-dependently inhibited IL-1β-induced degradation of 35 kDa IkB-α, with increasing recovery of IkB-α protein observed at higher concentrations.
Tepoxalin (0.45 mg/kg; p.o.) exhibits potent oral analgesic activity in mice (ED50 = 0.45 mg/kg) in the acetic acid-induced abdominal constriction assay[1].
Tepoxalin (0.015-2.37 mg/kg; p.o.) exhibits oral dose-dependent inhibition of ex vivo eicosanoid production in dogs, with greater potency for prostaglandin synthesis (ED50 = 0.015 mg/kg) than leukotriene synthesis (ED50 = 2.37 mg/kg)[1].
Tepoxalin (3-50 mg/kg; p.o.; 18 h and 1 h before stimulant injection) inhibits neutrophil migration into LPS- or TNF-α-induced murine cutaneous inflammatory sites in a dose-dependent manner, with a maximum 64.7% inhibition of LPS-induced MPO activity at 50 mg/kg, by suppressing NFκB-mediated upregulation of Mac-1 and E-selectin, and at the highest dose, ICAM-1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6, B6D2F1 (male, 8-12 weeks of age, intradermal injection of LPS or recombinant murine TNF-α-induced acute cutaneous inflammation)[2]
-
Dosage:3 mg/kg; 6 mg/kg; 12 mg/kg; 25 mg/kg; 50 mg/kg
-
Administration:p.o.; 18 h and 1 h before stimulant injection
-
Result:Inhibited LPS-induced MPO activity by 0% at 3 mg/kg, 33.6% at 6 mg/kg, 50.0% at 12 mg/kg, 54.3% at 25 mg/kg, and 64.7% at 50 mg/kg.
Inhibited TNF-α-induced MPO activity by 12.0% at 12 mg/kg, 54.7% at 25 mg/kg, and 61.2% at 50 mg/kg.
Reduced LPS-induced neutrophil extravasation and edema in skin tissue at 12, 25, and 50 mg/kg.
Suppressed LPS-induced upregulation of Mac-1 (CD18) on neutrophils and reduced E-selectin protein expression on vascular endothelial cells at 12, 25, and 50 mg/kg.
Reduced LPS-induced E-selectin mRNA levels to 6.3 × 10-22 moles/μg RNA at 25 mg/kg and did not alter ICAM-1 mRNA levels.
Reduced LPS-induced E-selectin mRNA levels to 4.8 × 10-22 moles/μg RNA and ICAM-1 mRNA levels to 9.7 × 10-22 moles/μg RNA at 50 mg/kg.
Caused no change in total leukocyte numbers or lymphocyte:monocyte:neutrophil ratios at 50 mg/kg compared to vehicle controls.
Chemical Information
-
CAS No. 103475-41-8
-
Appearance Solid
-
Masse moléculaire 385.84
-
Formule C20H20ClN3O3
-
Color Off-white to yellow
-
SMILES
O=C(N(O)C)CCC1=NN(C2=CC=C(OC)C=C2)C(C3=CC=C(Cl)C=C3)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (259.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (289 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Argentieri DC, et al. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther. 1994 Dec;271(3):1399-408. [Content Brief]
[2]. Zhou L, et al. Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. Eur J Immunol. 1996 Jan;26(1):120-9. [Content Brief]
[3]. Zhou L, et al. Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. J Immunol. 1994 Dec 1;153(11):5026-37. PMID: 7963563. [Content Brief]
[4]. Fiebich BL, et al. The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha. Neuropharmacology. 1999;38(9):1325-1333. [Content Brief]
[5]. Tam SS, et al. Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities. J Biol Chem. 1995;270(23):13948-13955. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5917 mL | 12.9587 mL | 25.9175 mL | 64.7937 mL |
| 5 mM | 0.5183 mL | 2.5917 mL | 5.1835 mL | 12.9587 mL | |
| 10 mM | 0.2592 mL | 1.2959 mL | 2.5917 mL | 6.4794 mL | |
| 15 mM | 0.1728 mL | 0.8639 mL | 1.7278 mL | 4.3196 mL | |
| 20 mM | 0.1296 mL | 0.6479 mL | 1.2959 mL | 3.2397 mL | |
| 25 mM | 0.1037 mL | 0.5183 mL | 1.0367 mL | 2.5917 mL | |
| 30 mM | 0.0864 mL | 0.4320 mL | 0.8639 mL | 2.1598 mL | |
| 40 mM | 0.0648 mL | 0.3240 mL | 0.6479 mL | 1.6198 mL | |
| 50 mM | 0.0518 mL | 0.2592 mL | 0.5183 mL | 1.2959 mL | |
| 60 mM | 0.0432 mL | 0.2160 mL | 0.4320 mL | 1.0799 mL | |
| 80 mM | 0.0324 mL | 0.1620 mL | 0.3240 mL | 0.8099 mL | |
| 100 mM | 0.0259 mL | 0.1296 mL | 0.2592 mL | 0.6479 mL |
Tepoxalin Related Classifications
HY-13219 Related Classifications
Powered by Bioz